tremelimumab sold brand name imjudo fully human monoclonal antibody used treatment hepatocellular carcinoma type liver tremelimumab designed attach block protein controls activity cells part immune system body natural common side effects used combination durvalumab include rash pruritus itching diarrhea abdominal belly pain increased levels liver enzymes fever hypothyroidism underactive thyroid gland cough peripheral edema swelling especially ankles feet increased level lipase enzyme helps digest fat mainly made tremelimumab approved medical use united states october european union february tremelimumab indicated combination durvalumab treatment adults unresectable hepatocellular tremelimumab combination durvalumab platinumbased chemotherapy indicated firstline treatment adults metastatic nonsmall cell lung cancer sensitizing epidermal growth factor receptor mutations anaplastic lymphoma kinase positive tremelimumab aims stimulate immune system attack tumors cytotoxic lymphocytes ctls recognize destroy cancer cells however also inhibitory mechanism immune checkpoint interrupts destruction tremelimumab turns inhibitory mechanism allows ctls continue destroy cancer like ipilimumab tremelimumab antibody binds protein expressed surface activated lymphocytes inhibits killing cancer tremelimumab blocks binding antigenpresenting cell ligands resulting inhibition downregulation tcell activation subsequently may interact another tcell surface receptor protein resulting tcell activation unopposed unlike ipilimumab another fully human monoclonal antibody isotype tremelimumab previously development investigation medimmune wholly owned subsidiary phase ii clinical studies metastatic melanoma showed however based early interim analysis phase iii data pfizer designated tremelimumab failure terminated trial april however within year survival curves showed separation treatment control although designated april orphan drug status tremelimumab failed improve lifespan phase iib determine trial assessed drug second thirdline treatment unresectable malignant phase iii trial astrazeneca paired tremelimumab inhibitor durvalumab firstline treatment nonsmall cell lung trial conducted across countries july astrazeneca announced failed meet primary endpoint progressionfree december committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product imjudo intended treatment hepatocellular applicant medicinal product astrazeneca tremelimumab approved medical use european union february tremelimumab international nonproprietary name immune activation dostarlimab ibalizumab httpsenwikipediaorgwikitremelimumab